Vanderkerken K - Search Results

1

Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.

De Beck L, Awad RM, Basso V, Casares N, De Ridder K, De Vlaeminck Y, Gnata A, Goyvaerts C, Lecocq Q, San José-Enériz E, Verhulst S, Maes K, Vanderkerken K, Agirre X, Prosper F, Lasarte JJ, Mondino A, Breckpot K. De Beck L, et al. Among authors: vanderkerken k. Front Immunol. 2022 May 12;13:799636. doi: 10.3389/fimmu.2022.799636. eCollection 2022. Front Immunol. 2022. PMID: 35634329 Free PMC article.

2

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.

Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E. Nur H, et al. Among authors: vanderkerken k. PLoS One. 2013 May 31;8(5):e65075. doi: 10.1371/journal.pone.0065075. Print 2013. PLoS One. 2013. PMID: 23741460 Free PMC article.

3

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E. Maes K, et al. Among authors: vanderkerken k. Cancers (Basel). 2013 Apr 15;5(2):430-61. doi: 10.3390/cancers5020430. Cancers (Basel). 2013. PMID: 24216985 Free PMC article.

4

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.

Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, McClue S, Vanderkerken K, De Bruyne E. Maes K, et al. Among authors: vanderkerken k. Oncotarget. 2014 May 30;5(10):3115-29. doi: 10.18632/oncotarget.1821. Oncotarget. 2014. PMID: 24833108 Free PMC article.

5

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.

Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, Nyegaard M, Schots R, Jernberg-Wiklund H, Vanderkerken K, De Bruyne E. Bieghs L, et al. Among authors: vanderkerken k. Oncotarget. 2014 Nov 30;5(22):11193-208. doi: 10.18632/oncotarget.1933. Oncotarget. 2014. PMID: 25008202 Free PMC article.

6

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E. Maes K, et al. Among authors: vanderkerken k. Oncotarget. 2015 Feb 20;6(5):3319-34. doi: 10.18632/oncotarget.3207. Oncotarget. 2015. PMID: 25669970 Free PMC article.

7

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.

Fristedt Duvefelt C, Lub S, Agarwal P, Arngården L, Hammarberg A, Maes K, Van Valckenborgh E, Vanderkerken K, Jernberg Wiklund H. Fristedt Duvefelt C, et al. Among authors: vanderkerken k. Oncotarget. 2015 Aug 21;6(24):20621-35. doi: 10.18632/oncotarget.4139. Oncotarget. 2015. PMID: 26036313 Free PMC article.

8

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.

Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E. Wang J, et al. Among authors: vanderkerken k. Oncotarget. 2015 Dec 22;6(41):43992-4004. doi: 10.18632/oncotarget.6083. Oncotarget. 2015. PMID: 26556857 Free PMC article.

9

Novel strategies to target the ubiquitin proteasome system in multiple myeloma.

Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Lub S, et al. Among authors: vanderkerken k. Oncotarget. 2016 Feb 9;7(6):6521-37. doi: 10.18632/oncotarget.6658. Oncotarget. 2016. PMID: 26695547 Free PMC article. Review.

10

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E. Lub S, et al. Among authors: vanderkerken k. Oncotarget. 2016 Jan 26;7(4):4062-76. doi: 10.18632/oncotarget.6768. Oncotarget. 2016. PMID: 26716651 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters